DLL3-TOPAbody

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameDLL3-TOPAbody
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersTumor necrosis factor receptor superfamily member 9 agonistsAnti-Delta-like protein 3
TargetsT cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 9Delta-like protein 3
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesConcept To Medicine Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesConcept To Medicine Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A